secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-001850
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports $455M cash, runway into 2H 2027; zanidatamab Phase 3 data expected 2024
--------------------------------------------------------------------------------

- Preliminary unaudited cash resources of $455M as of Dec 31, 2023; expected funding into second half of 2027.
- Top-line data from Phase 3 HERIZON-GEA-01 trial for zanidatamab in first-line HER2+ GEA expected in 2024.
- Regulatory reviews ongoing in 2024 for zanidatamab in second-line BTC in US and China with Jazz and BeiGene.
- IND filings planned for ZW171 and ZW191 in 2024; ZW220 and ZW251 in 2025; R&D Day in Q4 2024.
- Completed $50M private placement with EcoR1 Capital, contributing to extended cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524001850/0001193125-24-001850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524001850/d553940d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-001850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer